Amit J. Sabnis, MD, MS

Pediatric blood disorders and cancer specialist

Dr. Amit J. Sabnis is a hematologist-oncologist who cares for children with sarcomas, cancers of connective tissue that are more common in pediatric patients than adults.

In research, Sabnis uses genetic and biochemical tools to understand how sarcomas exploit normal cellular controls to allow abnormal rates of protein synthesis; the goal is to identify targets for new, selective drugs. He also collaborates closely with colleagues to turn laboratory findings into first-in-children trials measuring the safety and efficacy of new cancer therapies.

Sabnis earned a master's degree in biological sciences from Stanford University. At UCSF, he earned his medical degree and completed a residency in pediatrics and a fellowship in pediatric hematology and oncology, as well as additional training in biomedical research.

Clinics

Oncology Clinic
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 476-3831
Fax: (415) 502-4372

Precision Cancer Medicine Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 476-3831
Fax: (415) 502-4372

Solid Tumor Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 476-3831
Fax: (415) 502-4372

More about Amit J. Sabnis

Additional Languages

Spanish

Education

Stanford University, MS, Biological Sciences 2003
UCSF School of Medicine 2008

Residencies

UCSF, Pediatrics 2011

Fellowships

UCSF, Pediatric Hematology and Oncology 2014

Selected Research and Publications

  1. Cohen JN, Sabnis AJ, Krings G, Cho SJ, Horvai AE, Davis JL. EWSR1-NFATC2 Gene Fusion in a Soft Tissue Tumor with Epithelioid Round Cell Morphology and Abundant Stroma: A Case Report and Review of the Literature. Hum Pathol. 2018 Apr 04.
  2. Wattier RL, Levy ER, Sabnis AJ, Dvorak CC, Auerbach AD. Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services. Infect Control Hosp Epidemiol. 2017 Sep; 38(9):1039-1047.
  3. Sabnis AJ, Bivona TG. HSP70 dependence in rhabdomyosarcoma: Seed or soil? Cell Cycle. 2017 Jan 17; 16(2):147-148.
  4. Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016 08 09; 113(32):9015-20.
  5. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47.
  6. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
  7. Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28.
  8. Sabnis AJ, Bivona TG. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9.
  9. Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell. 2009 Apr 07; 15(4):341-52.
  10. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59.
  11. McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ, Zhang W, Fuchs H, de Angelis MH, Myers RM, Attardi LD, Barsh GS. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008 Aug; 40(8):963-70.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.